Secretin vs Cotadutide
Head-to-head comparison of Secretin (Human Secretin) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Secretin | Cotadutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Human Secretin | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 3055.4 Da | ~4,700 Da |
| Half-Life | 5-7 minutes | Approximately 24 hours |
| Amino Acids | 27 | 37 |
| Typical Dose | 0.2 mcg/kg IV | 0.3-3 mg daily in clinical studies |
| Route | Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 800 | 18 |
| Research Status | Clinical | Clinical |
Secretin Benefits
- ✓stimulates-pancreatic-secretion
- ✓supports-bicarbonate-release
- ✓aids-duodenal-pH-control
- ✓helps-digestive-coordination
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Secretin Dosing
0.2 mcg/kg IV diagnostic dose|research infusion protocols|short bolus administration
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Secretin Side Effects
- ⚠flushing
- ⚠nausea
- ⚠abdominal-cramping
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Secretin
Secretin is a classic GI hormone with extensive physiology literature and established diagnostic use. It remains important for studying pancreatic secretory function, biliary responses, and duodenal feedback.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.